Rosalind Advisors’s Regentis Biomaterials RGNT Stock Holding History

Rosalind Advisors’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.48M	Buy	701,685 +450,175	+179%	+$1.28M	0.92%	22
2026 Q1	$768K	Hold	251,510	–	–	0.31%	35
2025 Q4	$1.7M	Buy	+251,510	New	+$1.73M	0.6%	27

Other funds holding RGNT

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Rosalind Advisors's RGNT Position: Q2 2026 in Review

Rosalind Advisors increased its Regentis Biomaterials (RGNT) stake by 179% in Q2 2026, buying an estimated $1.28M and bringing the position to 701,685 shares worth $2.48M. The position accounts for 0.92% of the portfolio, ranked #22.

Rosalind Advisors first reported a position in RGNT in Q4 2025 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold RGNT as of Q2 2026.

Rosalind Advisors held 701,685 shares of Regentis Biomaterials worth $2.48M as of Q2 2026.
Rosalind Advisors bought 450,175 Regentis Biomaterials shares in Q2 2026, an estimated $1.28M.
Regentis Biomaterials made up 0.92% of Rosalind Advisors's portfolio in Q2 2026, its #22 holding.
Rosalind Advisors first reported a position in Regentis Biomaterials in Q4 2025 and has held it in 3 quarters since.
6 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.